Search - tctmd.com

Displaying 181 - 200 of 319

Sort: Relevancy | Date

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Daily News

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

Caitlin E. Cox

March 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Daily News

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Shelley Wood

January 15, 2019

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

Advertisement

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

No Need for Niacin? Meta-analysis Argues the End Is Nigh

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

No Free Brunch? Eggs Once Again Feel the Scramble in New, Large Observational Study

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases

Top News in Policy & Practice: 2018

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content